xerostomia

Medications linked to xerostomia and caries

Medications to control asthma, may predispose to dry mouth syndrome ( xerostomia) and caries. Researchers at the Medical University of South Carolina decided to examine whether there was a connection between// the two most common causes of absenteeism among school children asthma and caries. ...

Dry mouth linked to prescription and over the counter drugs

...new information about dry mouth. "The number of xerostomia cases has increased greatly over time because peop...re teeth) are also dry mouth symptoms. Over time, xerostomia sufferers may experience extensive tooth decay, to... those surveyed consider diagnosing a patient with xerostomia after he or she exhibits or reports symptoms of dr...

LSUHSC dental researcher funded to develop better dental materials

...ity of life, in particular for the vast number of people at high risk for cavities children, the elderly, those medically compromised who suffer from xerostomia or dry mouth, and those with mental or physical challenges," notes Dr. Xu. ...

Acupuncture Cuts Dry Mouth in Cancer Patients

...quality of life in patients with radiation-induced xerostomia is profoundly impaired," study senior author Mark ... at best." This study included 19 patients with xerostomia who'd completed radiation therapy at least four we...esulted in improvements in physical well-being and xerostomia symptoms, the researchers said. "Although the p...

Acupuncture eases radiation-induced dry mouth in cancer patients

...ncture treatments relieve debilitating symptoms of xerostomia - severe dry mouth - among patients treated with r...t in the current online issue of Head & Neck . xerostomia develops after the salivary glands have been expos...quality of life in patients with radiation-induced xerostomia is profoundly impaired," said Chambers, the study'...

Bi-Coastal Pharmaceutical Corp. Acquires U.S. Marketing Rights to Aquoral(TM) Artificial Saliva Product

... Exclusive prescription spray product to treat xerostomia will compete in $1 Billion US Market RED ...ostomia. The total US market for products treating xerostomia was estimated at $1 Billion in 2007. The product ...on be a trusted and proven household name to treat xerostomia as it is an extremely effective and easy to use pr...

TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects

...le product candidates each capable of treating a number of acute and chronic diseases and disorders such as migraine, chronic pain, muscle spasticity, xerostomia and cognitive disorders. The company is currently developing three product candidates: two ionotropic glutamate receptor antagonists and one muscarini...

CAPHOSOL results in minimal oral mucositis and pain in head/neck cancer patients

...s after initiation of therapy. Initial signs and symptoms include redness, swelling and ulceration of the mucosa. Oral mucositis can cause mouth pain, xerostomia (dryness of the mouth or throat), difficulty eating and drinking, as well as difficulty with speech; these effects can significantly impact a patient'...

TorreyPines Therapeutics Announces Management Change and Second Quarter 2008 Financial Results

...NGX267 as a treatment for xerostomia secondary to Sjogren's syndrome and the anticipated timing of results from the study of NGX267 as a treatment for xerostomia secondary to Sjogren's syndrome. Such statements are subject to numerous known and unknown risks, uncertainties and other factors, which may cause Tor...

TorreyPines Therapeutics Reports First Quarter 2008 Financial Results and Accomplishments

...cations for which they are developed, that the End of Phase II meeting will be held in the anticipated time frame, that NGX267 will successfully treat xerostomia secondary to Sjogren's syndrome, that the company's gamma secretase modulators will be able to successfully treat Alzheimer's disease or that TorreyPi...

xerostomia in Medical Technology

TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia

LA JOLLA, Calif., Dec. 2 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX ) today announced positive results from a 26 patient Phase II trial evaluating three doses of NGX267 as a treatment for xerostomia, or dry mouth, in patients with Sjogren's syndrome. NGX267 met the primary end...

Dry Mouth Linked to Prescription and Over the Counter Drugs

...cademy of General Dentistry (AGD). Dry mouth, or xerostomia , is caused by a decrease in salivary function. I...w information about dry mouth. "The number of xerostomia cases has increased greatly over time because peop...re teeth) are also dry mouth symptoms. Over time, xerostomia sufferers may experience extensive tooth decay, to...

BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting

...ntly associated with debility, and numerous physical and psychological symptoms including pain, dysphagia, weight loss, disfigurement, depression, and xerostomia (dry mouth). As a result, new and improved, and less toxic therapies for head and neck cancer are urgently required. About BioVex BioVex i...

Xalieve(TM) Gains Momentum as Calabar AB Launches a Phase II Repeated Dose Study in Dry Mouth Patients

... GOTEBORG, Sweden, October 2 /PRNewswire/ -- Calabar AB announced today that their Phase II repeated dose study in xerostomia ("dry mouth") patients has been initiated. Specifically, the drug will be studied in 45 dry mouth patients between the ages of 20 to 75. The objective...

Calabar AB Today Announced New Financing for Continuation of the Phase II Program in Patients With Dry Mouth

...r. Rook. About Calabar Calabar AB is a privately-held company committed to developing a pharmaceutical product addressing the great unmet needs of xerostomia "dry mouth". The company develops locally administered formulations of the cholinesterase inhibitor physostigmine, which has been shown to effectively...

ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study

...8) versus radiation alone (n=212) were mucositis-stomatitis (93%/94%), acneform rash (87%/10%), radiation dermatitis (86%/90%), weight loss (84%/72%), xerostomia (72%/71%), dysphagia (65%/63%), asthenia (56%/49%), nausea (49%/37%), constipation (35%/30%) and vomiting (29%/23%). The most common adverse events se...

TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia

... and neck, and HIV-related salivary gland disease. xerostomia can also be a side effect of some medications and ...ider initiating a small proof of concept study for xerostomia early next year." About TorreyPines Therapeutics ...e disorders, that the clinical trials for CIAS and xerostomia will be conducted in the anticipated timeframe or ...

Survival Data Available from Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer

...8) versus radiation alone (n=212) were mucositis-stomatitis (93%/94%), acneform rash (87%/10%), radiation dermatitis (86%/90%), weight loss (84%/72%), xerostomia (72%/71%), dysphagia (65%/63%), asthenia (56%/49%), nausea (49%/37%), constipation (35%/30%) and vomiting (29%/23%). The most common adverse events se...

Survival Data Available From Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer

...8) versus radiation alone (n=212) were mucositis-stomatitis (93%/94%), acneform rash (87%/10%), radiation dermatitis (86%/90%), weight loss (84%/72%), xerostomia (72%/71%), dysphagia (65%/63%), asthenia (56%/49%), nausea (49%/37%), constipation (35%/30%) and vomiting (29%/23%). The most common adverse events se...

Data Available from Erbitux Phase III Study in First-Line Treatment of Advanced Pancreatic Cancer

...8) versus radiation alone (n=212) were mucositis-stomatitis (93%/94%), acneform rash (87%/10%), radiation dermatitis (86%/90%), weight loss (84%/72%), xerostomia (72%/71%), dysphagia (65%/63%), asthenia (56%/49%), nausea (49%/37%), constipation (35%/30%) and vomiting (29%/23%). The most common adverse events se...

xerostomia in Medical Definition

Pathology

...cus retention cyst - Mumps - Necrotizing sialometaplasia - Ranula - Sialadenitis - Sialolithiasis - Sjogren's syndrome - Stomatitis - xerostomia Tongue Geographic tongue - Fissured tongue - Glossitis - Glossodynia v • d • e Health science -...

xerostomia in Biological News

Taste, odor intervention improves cancer therapy, according to Virginia Tech, Wake Forest study

...." They based their work on numerous previous studies that reported on changes in taste acuity, taste quality, odor perception, food aversion, and xerostomia (dry mouth) causing taste alteration. Findings from these studies showed changes in taste acuity are dependent on the site of the tumor with head and...

CAPHOSOL relieves oral mucositis and improves quality-of-life in cancer patients

...s after initiation of therapy. Initial signs and symptoms include redness, swelling and ulceration of the mucosa. Oral mucositis can cause mouth pain, xerostomia (dryness of the mouth or throat), difficulty eating and drinking, as well as difficulty with speech; these effects can significantly impact a patients...

xerostomia in Biological Technology

TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia

LA JOLLA, Calif., March 18 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX ) today announced it has initiated a Phase II study of NGX267, a muscarinic agonist in development for xerostomia, or dry mouth, secondary to Sjogren's syndrome. The company is conducting a randomized, d...

First Multiple Dose Clinical Trial of TorreyPines Therapeutics' Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated

...le product candidates each capable of treating a number of acute and chronic diseases and disorders such as migraine, chronic pain, muscle spasticity, xerostomia and cognitive disorders. The company is currently developing three product candidates: two ionotropic glutamate receptor antagonists and one muscarin...

TorreyPines Therapeutics Enters into Agreement to Reduce Royalty Rates and Delay Clinical Milestone Payments Due to Eli Lilly for NGX426 and Tezampanel

...le product candidates each capable of treating a number of acute and chronic diseases and disorders such as migraine, chronic pain, muscle spasticity, xerostomia and cognitive disorders. The company is currently developing three product candidates: two ionotropic glutamate receptor antagonists and one muscarini...

TorreyPines Therapeutics Appoints Evelyn Graham Chief Executive Officer and a Member of the Board of Directors

...le product candidates each capable of treating a number of acute and chronic diseases and disorders such as migraine, chronic pain, muscle spasticity, xerostomia and cognitive disorders. The company is currently developing three product candidates: two ionotropic glutamate receptor antagonists and one muscarini...

TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments

...such as migraine, chronic pain, muscle spasticity, xerostomia and cognitive disorders. The company is currently ... pain, the potential for NGX267 as a treatment for xerostomia secondary to Sjogren's syndrome, the anticipated t...esults from the study of NGX267 as a treatment for xerostomia secondary to Sjogren's syndrome, and the ability t...

TorreyPines Therapeutics Sells Alzheimer's Disease Genetics Program to Eisai

...e product candidates, each capable of treating a number of acute and chronic diseases and disorders such as migraine, chronic pain, muscle spasticity, xerostomia and cognitive disorders. The company is currently developing three product candidates: two ionotropic glutamate receptor antagonists and one muscarini...

TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel

...e product candidates, each capable of treating a number of acute and chronic diseases and disorders such as migraine, chronic pain, muscle spasticity, xerostomia and cognitive disorders. The company is currently developing three product candidates: two ionotropic glutamate receptor antagonists and one muscarini...

TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel

...ase II study of NGX267, our muscarinic agonist, in xerostomia secondary to Sjogren's syndrome." About Tezampan...such as migraine, chronic pain, muscle spasticity, xerostomia and cognitive disorders. The company is currently ... pain, the potential for NGX267 as a treatment for xerostomia secondary to Sjogren's syndrome, the anticipated t...

TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds

...such as migraine, chronic pain, muscle spasticity, xerostomia and cognitive disorders. The company is currently ...esults from the study of NGX267 as a treatment for xerostomia secondary to Sjogren's syndrome, the anticipated t...ed time frame, that NGX267 will successfully treat xerostomia secondary to Sjogren's syndrome, that TorreyPines ...

TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights

... and NGX267, our lead M1 agonist, that is currently in a Phase II trial for xerostomia secondary to Sjogren's syndrome." 2007 Highlights: -- Tezampanel met ... be held in the anticipated time frame, that NGX267 will successfully treat xerostomia secondary to Sjogren's syndrome, or that TorreyPines will be able to comple...